CAMP4 Therapeutics (CAMP) said Tuesday data from single ascending dose portion of an early-stage study of CMP-CPS-001 for the treatment of urea cycle disorders showed "favorable" safety results.
"We are pleased to report the safety data from the SAD portion of our Phase 1 study of CMP-CPS-001 for UCDs, showing that the drug has been well-tolerated," said Chief Medical Officer Yuri Maricich.
"We expect 2025 to be a pivotal year as we anticipate reporting MAD safety and key biomarker data in the second half of 2025," Maricich said. MAD refers to multiple ascending dose.
"Results from these studies could enable us to advance the CMP-CPS-001 program into a registrational Phase 2/3 trial in 2026."
Shares of the company were advancing over 4% in after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。